Global Hydroxychloroquine for COVID-19 Market Size, Share, and Trends Analysis Report, By Application (Hospitals, Clinics, and COVID-19 Care Centres), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The hydroxychloroquine for COVID-19 market is anticipated to grow at a significant CAGR of 3.4% during the forecast period (2022-2028). Hydroxychloroquine raises endosomal pH, which prevents SARS-CoV-2 from fusing to the host cell membrane.  Chloroquine prevents the cellular angiotensin-converting enzyme 2 (ACE2) receptor from being glycosylated, which may prevent SARS-CoV from attaching to the cell receptor.  In vitro investigations, it has been revealed that hydroxychloroquine may prevent the viral genome from being released by blocking the transfer of SARS-CoV-2 from early endosomes to endolysosomes. Immunomodulatory actions of hydroxychloroquine have also been proposed as a possible mechanism of action for the treatment of COVID-19. The major factor driving the growth of the global hydroxychloroquine for COVID-19 market is the rising cases of COVID-19 globally.

The global hydroxychloroquine for COVID-19 market is segmented based on type and application. Based on type, the market is sub-segmented into hospitals, clinics, and COVID-19 care centres. Based on the distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Among these distribution channels, the hospital segment is expected to propel the growth of the market due to the increasing usage of hydroxychloroquine drugs in the treatment of COVID-19 patients. Although the drug is not approved officially by the USFDA, it is being used heavily in the treatment of COVID-19 patients. The FDA assessed that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the permitted purposes under the EUA based on its ongoing study of the EUA and developing scientific evidence.

Some of the major players in the market include Bayer AG, Rising Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Shanghai Pharma Ltd., Novartis International AG, and Sanofi SA, among others. The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bayer AG, Rising Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Shanghai Pharma Ltd., Novartis International AG, and Sanofi SA, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hydroxychloroquine for COVID-19 Market Report by Segment

By Application

• Hospitals
• Clinics
• COVID-19 Care Centres

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Hydroxychloroquine for COVID-19 Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa